Some of the features of BioRunUp.com include:

- Detailed Reports on Upcoming FDA and Clinical Trial Trades
- REAL TIME Posting of Trades (Entries and Exits)
- Clinical and Regulatory Catalyst Database with over 400 events and updated daily
- Members Only Live Interactive Webinars
- Live Chat Room
- Video Lessons / Trade Reviews
- Run-Up Valuation Studies
- Weekly Video Watchlist
- SMS Alerts of breaking biotech news
- Access to Mark Messier and Mike Havrilla's Trading Accounts 
- Watch FOUR Profitable Biotech Traders in Real Time
- A More Detailed FDA Calendar
- Historical FDA Tracker
- Bio-Pharma, FDA, Clinical Trials, and Stock Market News Updates
- Direct Email Communication
- Affiliate Program

The cost for an annual subscription is $697 and includes all the above features. We also offer a monthly plan for $99.95

 CLICK HERE TO JOIN BIORUNUP



Sign up for our free newsletter. 
It’s the best way to stay informed about upcoming catalysts, new website content, and special announcements / offers.

 


Recent Profits of over $1,200,000


Take a look at excerpts from BioRunUp subscriber testimonials:

"My most recent and profitable trade are the EXAS Oct $5 options which I purchased at $.40 off of BioRunUp blog alert. They are currently yielding a 700% return!!!"

"Within 1 month my brand new porfolio was up over 23%!"

"In the first month I made a 13% return, doubling the return of the market as a whole - without leverage. To date, I have never failed to beat the market when applying the methods outlined in the pages of BioRunUp."

"I don’t ever take recommendations from people on the Internet, but this one looked right, felt right and sounded right. Thanks BioRunUp, you made me a fortune."


To read more testimonials, click HERE

 

 

Recent articles

 

$ZGNX Zogenix Seeks Approval For Abuse-Deterrent Zohydro ER

(in: Articles)
 

$CERS Cerus: Blood Filtration Device Specialist With Multiple Catalysts

(in: Articles)
 

This Week's Watchlist 10/20/14

(in: Articles)
 

$XOMA Poised For Run-Up Into Phase 3 Results

(in: Articles)
 

$ADMS Adamas Pharma: CNS Specialist With Early 2015 PDUFA Catalyst

(in: Articles)
 

10/14/14 Catalyst Summary

(in: Articles)
 

$AEZS Aeterna Zentaris Plunges Ahead Of Near-Term PDUFA Catalyst

(in: Articles)
 

$CEMP $TTPH Previewing A Pair Of Antibiotic Phase 3 Catalyst Trades

(in: Articles)
 

This Week's Watchlist 10/13/14

(in: Articles)
 

$RMTI Rockwell Medical Seeks To Expand Dialysis Product Mix

(in: Articles)
 

$ARWR Arrowhead Sinks On Disappointing Phase 2 Abstract Data

(in: Articles)
 

This Week's Watchlist 10/6/14

(in: Articles)
 

BioRunUp Webinar - THURSDAY 10/2/14 4:30pm ET

(in: Articles)
 

$PGNX Progenics: After Relistor Approval, Focus Shifts To Cancer Pipeline

(in: Articles)
 

$AKBA Akebia: Near-Term Phase 2b Catalyst For Anemia Drug Candidate

(in: Articles)
 

This Week's Watchlist 9/29/14

(in: Articles)
 

9/26/14 Catalyst Calendar Summary

(in: Articles)
 

9/23/14 Catalyst Calendar Update

(in: Articles)
 

$SGYP Synergy Pharma: GI Specialist With Phase 2 & 3 Catalysts

(in: Articles)
 

$NKTR Nektar: Drug Delivery Specialist With Multiple Catalysts

(in: Articles)